Please Wait.....
Report
Epilepsy Drugs Market Growth Analysis - Forecast Trends and Outlook (2025-2034)
Market Report I 2025-06-20 I 400 Pages I EMR Inc.
The epilepsy drugs market was valued at USD 8193.50 Million in 2024 , driven by the rising prevalence of epilepsy and neurological disorders across the 8 major markets. The market is expected to grow at a CAGR of 4.40 % during the forecast period of 2025-2034, with the values likely to attain USD 12603.01 Million by 2034 .
Epilepsy Drugs Market Overview
Epilepsy is a neurological disorder characterised by recurrent seizures, affecting millions globally. The epilepsy drugs market is driven by the increasing prevalence of epilepsy, due to which the need for the development of innovative antiepileptic drugs (AEDs) by pharmaceutical companies has heightened. The market is fuelled by the escalating advancements in personalised medicine and diagnostic technologies. The rising efforts to increase awareness among people about the available treatments are also contributing to the market growth. With expanding healthcare infrastructure in developing regions, the epilepsy drugs market is poised for substantial growth.
Epilepsy Drugs Market Growth Factors
Regulatory Approvals Marking Significant Milestones in Epilepsy Treatment
In January 2024, the Japanese Ministry of Health, Labour and Welfare approved Fycompa (perampanel), the injection form of an antiepileptic drug (AED) in Japan. The drug is an internally developed product of Eisai Co., Ltd and has been approved particularly as an alternative during situations when oral administration is temporarily impossible. Fycompa, an innovative AED discovered at Eisai's Tsukuba Research Laboratories. It acts as a highly selective, noncompetitive AMPA receptor antagonist, aiming to mitigate neuronal hyper-excitation associated with seizures by modulating glutamate activity.
This injection offers continuity in epilepsy patients by addressing concerns of interrupted treatment during situations like surgeries. Being the sole AMPA receptor antagonist-based AED, this expansion of Fycompa's administration route facilitates patients who are unable to use oral medication temporarily. The major focus of Eisai Co., Ltd has always been neurology, and epilepsy in particular.This development aligns with the company's vision to enhance the quality of life for epilepsy patients. Such innovative drug developments and expanded treatment options are poised to drive the market growth, meeting the diverse needs of patients worldwide and potentially driving market expansion in the forecast period.
Surge in Drug Development Initiatives to Meet Rising the Epilepsy Drugs Market Demand
In October 2023, a groundbreaking study discovered the efficacy of an investigational medication, XEN1101, in significantly reducing seizure frequency. The medication demonstrated a reduction of more than 50 percent in some patients and even eliminated seizures overall in some patients, which is a significant advancement in epilepsy treatment. The positive findings from the phase 2b clinical trial conducted at NYU Grossman School of Medicine underscore XEN1101's potential as a swift, safe, and effective adjunctive therapy for focal epilepsy.
As XEN1101 offers a novel mechanism of action as a potassium-channel opener, it represents a significant breakthrough in epilepsy drug development. These promising results are poised to drive substantial growth in the market as patients and healthcare providers increasingly embrace this innovative treatment option. Such advancements also contribute to expanding pharmaceutical companies' market opportunities and fostering advancements in epilepsy care worldwide, fuelling the market growth.
Epilepsy Drugs Market Trends
Increasing Prevalence of the Condition
The rising prevalence of neurological disorders including epilepsy is contributing to the growth of the global epilepsy drug market._x000D_
Advancement in Drug Development
Pharmaceutical companies continue to invest in research and development in order to introduce new and improved antiepileptic drugs (AEDs). Such advancements are poised to boost market growth. These drugs aim to provide better efficacy, fewer side effects, and improved patient compliance compared to traditional treatments._x000D_
Demand for Generic Drugs
The significant presence of generic drugs and latest patent expirations drive the market growth. Patent expirations of several blockbuster AEDs have led to the entry of generic versions, driving competition and increased cost-effectiveness._x000D_
Rising Awareness Around the Condition
Increasing efforts to raise awareness about epilepsy and reduce the stigma associated with the condition are encouraging more individuals to seek diagnosis and treatment. This heightened awareness contributes to market growth.
Epilepsy Drugs Market Segmentation
Market Breakup by Seizure Type
- Focal Seizures
- Generalized Seizures
- Non-epileptic Seizures
- Others
Market Breakup by Drug Generation
- First Generation Drugs
- Second Generation Drugs
- Third Generation Drugs
Market Breakup by Age Group
- Pediatric
- Geriatric
- Adult
Market Breakup by Route of Administration
- Oral
- Nasal
- Injectable
- Others
Market Breakup by Distribution Channel
- Hospital Pharmacies
- Drug Stores and Retail Pharmacies
- Online Providers
Market Breakup by Region
- United States
- EU-4 and the United Kingdom
- Japan
- India
Epilepsy Drugs Market Share
Focal Seizures Lead Seizure Type Segmentation
Seizure type segmentation includes focal seizures, generalized seizures, non-epileptic seizures, and others. Focal seizures lead the market segment due to their prevalence and distinct characteristics. Focal seizures require targeted treatment approaches, driving pharmaceutical companies to develop specialised medications, tailored to address the unique needs of patients experiencing focal epilepsy.
First Generation Dominates the Drug Generation Segmentation
Market share based on drug generation includes first-generation drugs, second-generation drugs, and third-generation drugs. Out of these, first-generation drugs dominate the drug generation segmentation in the global market. This can be attributed to its established efficacy, familiarity among physicians, and lower cost compared to newer generations.
Oral Route of Administration Most Preferred
Market segmentation based on the route of administration includes oral, nasal, injectable, and others. The oral route of administration is most preferred in the global epilepsy drugs market due to its convenience, ease of use, and high patient acceptance. Oral medications offer flexible dosing regimens while providing efficient systemic drug delivery simultaneously, contributing to better seizure management and patient compliance.
Epilepsy Drugs Market Analysis by Region
Based on the regional analysis, the market covers United States, EU-4 (Germany, France, Italy, Spain)and the United Kingdom, Japan and India, with each region contributing to the overall dynamics of the market. The United States leads the epilepsy drugs market due to factors such as an increasing prevalence of the condition, presence of advanced healthcare infrastructure, robust research and development activities, and significant investments in innovative drug therapies. Additionally, favorable regulatory policies and strong market competition contribute to the region's dominance in the market.
Further, Japan and India are witnessing steady growth due to rising prevalence, improving healthcare infrastructure, increasing awareness, and better access to treatment options. The region is poised to witness a significant growth in the forecast period.
Leading Players in the Epilepsy Drugs Market
The key features of the market report include patent analysis, grants analysis, clinical trial analysis, and latest strategic initiatives by the leading players. The major companies in the market are as follows:
GlaxoSmithKline Plc
GlaxoSmithKline Plc (GSK) was established in 2000 and is currently headquartered in Brentford, London. It is a prominent pharmaceutical company with a significant market presence. Some of the well-known epilepsy drugs include Lamictal (Lamotrigine), Epanutin (Phenytoin) and Trobalt (Retigabine) among others.
Eisai Co., Ltd.
It is a leading pharmaceutical company based out of Japan. This company is dedicated to develop and discover several effective drugs that address the different needs of patients.
Novartis AG
It is a Swiss multinational pharmaceutical company based out of Switzerland and known for its elaborate portfolio of epilepsy drugs. Tegretol (Carbamazepine), Trileptal (Oxcarbazepine) and Sabril (Vigabatrin) are some of the examples.
Other companies in the market include UCB Pharma S.A, Sanofi, S K Biopharmaceuticals, Novel Laboratories Inc., Pfizer Inc., Neurelis, Inc., Bausch Health Companies Inc., Dr. Reddy's Laboratories, Sumitomo Pharma, Jazz Pharmaceuticals, Inc., Sun Pharmaceuticals Industries Ltd. and Alkem Laboratories Ltd.
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Queries Solved in the Epilepsy Drugs Market Report
- What was the epilepsy drugs market value in 2024?
- What is the epilepsy drugs market forecast outlook for 2025-2034?
- What are the major factors aiding the market demand?
- What are the major market trends?
- What is the market segmentation based on the seizure type?
- What is the market breakup by drug generation?
- How is the market segmented based on the route of administration?
- What are segments based on distribution channels?
- Which age group does this drug serve?
- What are the major markets according to the Expert Market Research report?
- Who are the key players in the epilepsy drugs market?
- How will the market landscape evolve in the upcoming years?
- What are the major drivers, opportunities, and restraints in the market?
- What will be the effect of each driver, challenge, and opportunity on the market?
- Which country is poised to lead the market share in the forecast period?
- Which segment has the highest impact on the market size?
- What is the patent landscape of the market?
- What drugs are currently under clinical trials?
- How are partnerships, collaborations, mergers and acquisitions shaping the market dynamics?
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Epilepsy Drugs Market Overview: 8 Major Market
3.1 Epilepsy Drugs Market Historical Value (2018-2024)
3.2 Epilepsy Drugs Market Forecast Value (2025-2034)
4 Vendor Positioning Analysis
4.1 Key Vendors
4.2 Prospective Leaders
4.3 Niche Leaders
4.4 Disruptors
5 Epilepsy: Disease Overview
5.1 Guidelines and Stages
5.2 Pathophysiology
5.3 Screening and Diagnosis
5.4 Therapy Pathway
6 Patient Profile
6.1 Patient Profile Overview
6.2 Patient Psychology and Emotional Impact Factors
6.3 Risk Assessment and Therapy Success Rate
7 Epilepsy Epidemiology Scenario and Forecast - 8 Major Markets
7.1 8MM Epidemiology Scenario Overview (2018-2034)
7.1.1 Prevalence, by Country
7.1.1.1 U.S.
7.1.1.2 U.K.
7.1.1.3 EU4
7.1.1.4 India
7.1.1.5 Japan
7.1.2 Mortality, by Country
7.1.2.1 U.S.
7.1.2.2 U.K.
7.1.2.3 EU4
7.1.2.4 India
7.1.2.5 Japan
7.1.3 Treatment Seeking Rate, by Country
7.1.3.1 U.S.
7.1.3.2 U.K.
7.1.3.3 EU4
7.1.3.4 India
7.1.3.5 Japan
8 Epilepsy Drugs Market Landscape: 8 Major Market*
8.1 Epilepsy Drugs Market: Developers Landscape
8.1.1 Analysis by Year of Establishment
8.1.2 Analysis by Company Size
8.1.3 Analysis by Region
8.2 Epilepsy Drugs Market: Product Landscape
8.2.1 Analysis by Seizure Type
8.2.2 Analysis by Drug Generation
9 Epilepsy Market Therapy Challenges and Unmet Needs
9.1 Therapy Pathway Challenges
9.2 Compliance and Drop-Out Analysis
9.3 Awareness and Prevention Gaps
10 Cost of Therapy
11 Epilepsy Drugs Market Dynamics
11.1 Market Drivers and Constraints
11.2 SWOT Analysis
11.2.1 Strengths
11.2.2 Weaknesses
11.2.3 Opportunities
11.2.4 Threats
11.3 PESTEL Analysis
11.3.1 Political
11.3.2 Economic
11.3.3 Social
11.3.4 Technological
11.3.5 Legal
11.3.6 Environment
11.4 Porter's Five Forces Model
11.4.1 Bargaining Power of Suppliers
11.4.2 Bargaining Power of Buyers
11.4.3 Threat of New Entrants
11.4.4 Threat of Substitutes
11.4.5 Degree of Rivalry
11.5 Key Demand Indicators
11.6 Key Price Indicators
11.7 Industry Events, Initiatives, and Trends
11.8 Value Chain Analysis
12 Epilepsy Drugs Market Segmentation (218-2034): 8 Major Market
12.1 Epilepsy Drugs Market (2018-2034) by Seizure Type
12.1.1 Market Overview
12.1.2 Focal Seizures
12.1.3 Generalized Seizures
12.1.4 Non-epileptic Seizures
12.1.5 Others
12.2 Epilepsy Drugs Market (2018-2034) by Drug Generation
12.2.1 Market Overview
12.2.2 First Generation Drugs
12.2.3 Second Generation Drugs
12.2.4 Third Generation Drugs
12.3 Epilepsy Drugs Market (2018-2034) by Age Group
12.3.1 Market Overview
12.3.2 Pediatric
12.3.3 Geriatric
12.3.4 Adult
12.4 Epilepsy Drugs Market (2018-2034) by Route of Administration
12.4.1 Market Overview
12.4.2 Oral
12.4.3 Nasal
12.4.4 Injectable
12.4.5 Others
12.5 Epilepsy Drugs Market (2018-2034) by Distribution Channel
12.5.1 Market Overview
12.5.2 Hospital Pharmacies
12.5.3 Drug Stores and Retail Pharmacies
12.5.4 Online Providers
12.6 Epilepsy Drugs Market (2018-2034) by Region
12.6.1 Market Overview
12.6.2 United States
12.6.3 EU-4 and the United Kingdom
12.6.3.1 Germany
12.6.3.2 France
12.6.3.3 Italy
12.6.3.4 Spain
12.6.3.5 United Kingdom
12.6.4 Japan
12.6.5 India
13 United States Epilepsy Drugs Market (218-2034)
13.1 United States Epilepsy Drugs Market Historical Value (2018-2024)
13.2 United States Epilepsy Drugs Market Forecast Value (2025-2034)
13.3 United States Epilepsy Drugs Market (2018-2034) by Seizure Type
13.3.1 Market Overview
13.3.2 Focal Seizures
13.3.3 Generalized Seizures
13.3.4 Non-epileptic Seizures
13.3.5 Others
13.4 United States Epilepsy Drugs Market (2018-2034) by Drug Generation
13.4.1 Market Overview
13.4.2 First Generation Drugs
13.4.3 Second Generation Drugs
13.4.4 Third Generation Drugs
13.5 United States Epilepsy Drugs Market (2018-2034) by Age Group
13.5.1 Market Overview
13.5.2 Pediatric
13.5.3 Geriatric
13.5.4 Adult
13.6 United States Epilepsy Drugs Market (2018-2034) by Route of Administration
13.6.1 Market Overview
13.6.2 Oral
13.6.3 Nasal
13.6.4 Others
13.7 United States Epilepsy Drugs Market (2018-2034) by Distribution Channel
13.7.1 Market Overview
13.7.2 Hospital Pharmacies
13.7.3 Drug Stores and Retail Pharmacies
13.7.4 Online Providers
14 EU-4 and United Kingdom Epilepsy Drugs Market (218-2034)
14.1 EU-4 and United Kingdom Epilepsy Drugs Market Historical Value (2018-2024)
14.2 EU-4 and United Kingdom Epilepsy Drugs Market Forecast Value (2025-2034)
14.3 EU-4 and United Kingdom Epilepsy Drugs Market (2018-2034) by Seizure Type
14.3.1 Market Overview
14.3.2 Focal Seizures
14.3.3 Generalized Seizures
14.3.4 Non-epileptic Seizures
14.3.5 Others
14.4 EU-4 and United Kingdom Epilepsy Drugs Market (2018-2034) by Drug Generation
14.4.1 Market Overview
14.4.2 First Generation Drugs
14.4.3 Second Generation Drugs
14.4.4 Third Generation Drugs
14.5 EU-4 and United Kingdom Epilepsy Drugs Market (2018-2034) by Age Group
14.5.1 Market Overview
14.5.2 Pediatric
14.5.3 Geriatric
14.5.4 Adult
14.6 EU-4 and United Kingdom Epilepsy Drugs Market (2018-2034) by Route of Administration
14.6.1 Market Overview
14.6.2 Oral
14.6.3 Nasal
14.6.4 Injectable
14.6.5 Others
14.7 EU-4 and United Kingdom Epilepsy Drugs Market (2018-2034) by Distribution Channel
14.7.1 Market Overview
14.7.2 Hospital Pharmacies
14.7.3 Drug Stores and Retail Pharmacies
14.7.4 Online Providers
15 Japan Epilepsy Drugs Market
15.1 Japan Epilepsy Drugs Market Historical Value (2018-2024)
15.2 Japan Epilepsy Drugs Market Forecast Value (2025-2034)
15.3 Japan Epilepsy Drugs Market (2018-2034) by Seizure Type
15.3.1 Market Overview
15.3.2 Focal Seizures
15.3.3 Generalized Seizures
15.3.4 Non-epileptic Seizures
15.3.5 Others
15.4 Japan Epilepsy Drugs Market (2018-2034) by Drug Generation
15.4.1 Market Overview
15.4.2 First Generation Drugs
15.4.3 Second Generation Drugs
15.4.4 Third Generation Drugs
15.5 Japan Epilepsy Drugs Market (2018-2034) by Age Group
15.5.1 Market Overview
15.5.2 Pediatric
15.5.3 Geriatric
15.5.4 Adult
15.6 Japan Epilepsy Drugs Market (2018-2034) by Route of Administration
15.6.1 Market Overview
15.6.2 Oral
15.6.3 Nasal
15.6.4 Injectable
15.6.5 Others
15.7 Japan Epilepsy Drugs Market (2018-2034) by Distribution Channel
15.7.1 Market Overview
15.7.2 Hospital Pharmacies
15.7.3 Drug Stores and Retail Pharmacies
15.7.4 Online Providers
16 India Epilepsy Drugs Market
16.1 India Epilepsy Drugs Market (2018-2034) Historical Value (2018-2024)
16.2 India Epilepsy Drugs Market (2018-2034) Forecast Value (2025-2034)
16.3 India Epilepsy Drugs Market (2018-2034) by Seizure Type
16.3.1 Market Overview
16.3.2 Focal Seizures
16.3.3 Generalized Seizures
16.3.4 Non-epileptic Seizures
16.3.5 Others
16.4 India Epilepsy Drugs Market (2018-2034) by Drug Generation
16.4.1 Market Overview
16.4.2 First Generation Drugs
16.4.3 Second Generation Drugs
16.4.4 Third Generation Drugs
16.5 India Epilepsy Drugs Market (2018-2034) by Age Group
16.5.1 Market Overview
16.5.2 Pediatric
16.5.3 Geriatric
16.5.4 Adult
16.6 India Epilepsy Drugs Market (2018-2034) by Route of Administration
16.6.1 Market Overview
16.6.2 Oral
16.6.3 Nasal
16.6.4 Injectable
16.6.5 Others
16.7 India Epilepsy Drugs Market (2018-2034) by Distribution Channel
16.7.1 Market Overview
16.7.2 Hospital Pharmacies
16.7.3 Drug Stores and Retail Pharmacies
16.7.4 Online Providers
17 Regulatory Framework
17.1 Regulatory Overview
17.1.1 US FDA
17.1.2 EU EMA
17.1.3 INDIA CDSCO
17.1.4 JAPAN PMDA
17.1.5 Others
18 Patent Analysis
18.1 Analysis by Type of Patent
18.2 Analysis by Publication Year
18.3 Analysis by Issuing Authority
18.4 Analysis by Patent Age
18.5 Analysis by CPC Analysis
18.6 Analysis by Patent Valuation
18.7 Analysis by Key Players
19 Clinical Trial Analysis
19.1 Analysis by Trial Registration Year
19.2 Analysis by Trial Status
19.3 Analysis by Trial Phase
19.4 Analysis by Therapeutic Area
19.5 Analysis by Geography
20 Grants Analysis
20.1 Analysis by Year
20.2 Analysis by Amount Awarded
20.3 Analysis by Issuing Authority
20.4 Analysis by Grant Application
20.5 Analysis by Funding Institute
20.6 Analysis by Departments
20.7 Analysis by Recipient Organization
21 Strategic Analysis
21.1 Analysis by Partnership Instances
21.2 Analysis by Type of Partnership
21.3 Analysis by Leading Players
21.4 Analysis by Geography
22 Supplier Landscape
22.1 Market Share by Top 5 Companies
22.2 UCB Pharma S.A
22.2.1 Financial Analysis
22.2.2 Product Portfolio
22.2.3 Demographic Reach and Achievements
22.2.4 Mergers and Acquisitions
22.2.5 Certifications
22.3 GlaxoSmithKline Plc
22.3.1 Financial Analysis
22.3.2 Product Portfolio
22.3.3 Demographic Reach and Achievements
22.3.4 Mergers and Acquisitions
22.3.5 Certifications
22.4 Sanofi
22.4.1 Financial Analysis
22.4.2 Product Portfolio
22.4.3 Demographic Reach and Achievements
22.4.4 Mergers and Acquisitions
22.4.5 Certifications
22.5 S K Biopharmaceuticals
22.5.1 Financial Analysis
22.5.2 Product Portfolio
22.5.3 Demographic Reach and Achievements
22.5.4 Mergers and Acquisitions
22.5.5 Certifications
22.6 Eisai Co., Ltd .
22.6.1 Financial Analysis
22.6.2 Product Portfolio
22.6.3 Demographic Reach and Achievements
22.6.4 Mergers and Acquisitions
22.6.5 Certifications
22.7 Novartis AG
22.7.1 Financial Analysis
22.7.2 Product Portfolio
22.7.3 Demographic Reach and Achievements
22.7.4 Mergers and Acquisitions
22.7.5 Certifications
22.8 Novel Laboratories Inc .
22.8.1 Financial Analysis
22.8.2 Product Portfolio
22.8.3 Demographic Reach and Achievements
22.8.4 Mergers and Acquisitions
22.8.5 Certifications
22.9 Pfizer Inc .
22.9.1 Financial Analysis
22.9.2 Product Portfolio
22.9.3 Demographic Reach and Achievements
22.9.4 Mergers and Acquisitions
22.9.5 Certifications
22.10 Neurelis, Inc .
22.10.1 Financial Analysis
22.10.2 Product Portfolio
22.10.3 Demographic
22.10.4 Mergers and Acquisitions
22.10.5 Certifications
22.11 Dr. Reddy's Laboratories
22.11.1 Financial Analysis
22.11.2 Product Portfolio
22.11.3 Demographic Reach and Achievements
22.11.4 Mergers and Acquisitions
22.11.5 Certifications
22.12 Sumitomo Pharma
22.12.1 Financial Analysis
22.12.2 Product Portfolio
22.12.3 Demographic Reach and Achievements
22.12.4 Mergers and Acquisitions
22.12.5 Certifications
22.13 Jazz Pharmaceuticals, Inc .
22.13.1 Financial Analysis
22.13.2 Product Portfolio
22.13.3 Demographic Reach and Achievements
22.13.4 Mergers and Acquisitions
22.13.5 Certifications
22.14 Sun Pharmaceuticals Industries Ltd .
22.14.1 Financial Analysis
22.14.2 Product Portfolio
22.14.3 Demographic Reach and Achievements
22.14.4 Mergers and Acquisitions
22.14.5 Certifications
22.15 Alkem Laboratories Ltd
22.15.1 Financial Analysis
22.15.2 Product Portfolio
22.15.3 Demographic Reach and Achievements
22.15.4 Mergers and Acquisitions
22.15.5 Certifications
23 Epilepsy Drugs Market - Distribution Model (Additional Insight)
23.1 Overview
23.2 Potential Distributors
23.3 Key Parameters for Distribution Partner Assessment
24 Key Opinion Leaders (KOL) Insights (Additional Insight)
25 Payment Methods (Additional Insight)
25.1 Government Funded
25.2 Private Insurance
25.3 Out-of-Pocket
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security